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ABSTRACT
Background    Genetic diagnoses provide beneficial in-
formation to patients and families. However, traditional 
genetic diagnoses are often difficult even for experi-
enced clinicians and require recognition of characteristic 
patterns of signs or symptoms to guide targeted genetic 
testing for the confirmation of diagnoses. Next-genera-
tion sequencing (NGS) is a powerful genetic diagnostic 
tool. However, whole-genome and whole-exome se-
quencing (WES) are expensive, and the interpretation of 
results is difficult. Hence, target gene capture sequencing 
of gene panels has recently been applied to genetic diag-
noses. Herein, we demonstrate that targeted sequencing 
approaches using gene panel testing are highly efficient 
for the diagnosis of Mendelian disorders.
Methods    NGS using TruSight one gene panel was 
performed in 17 families and 20 patients, and we de-
veloped a bioinformatic pipeline at our institution for 
detecting mutations.
Results    We detected causative mutations in 6 of 17 
(35%) families. In particular, 11 (65%) families had 
syndromic diagnosis and 6 (35%) had no syndromic 
diagnosis before NGS testing. The number of positive 
diagnoses was 5 of 11 (45%) in the syndromic group and 
were 1 of 6 (17%) among patients of the no syndromic 
diagnosis group.
Conclusion    Diagnostic yields in the present study 
were higher than in previous reports of genetic and chro-
mosomal tests and WES. The present comprehensive 
gene-targeted panel test is a powerful diagnostic tool for 
Mendelian disorders.
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Traditional genetic diagnosis requires the recognition of 
characteristic patterns of signs or symptoms to guide tar-
geted genetic testing for the confirmation of diagnoses. 
Because genetic diagnoses are often difficult, even for 
experienced clinicians, the traditional approach for di-
agnosing patients with suspected genetic disorders is on 
the threshold of a paradigm shift due to next-generation 
sequencing (NGS). Whole-exome sequencing (WES) 
was first used in 2010 to identify causative genes of a 
Mendelian disease1 and is rapidly becoming an attractive 
tool for diagnostic testing in general medical genetics.
 Typical exomes contain more than 30,000 variants 
compared with human reference sequences and approxi-
mately 10,000 of these represent nonsynonymous amino 
acid substitutions, alterations of conserved splice site 
residues, or small insertions or deletions.2 Thus, subse-
quent steps are required to determine the significance 
of mutations by identifying benign variants, and genetic 
diagnoses using NGS remain challenging.
 NGS is performed by sequencing small DNA frag-
ments, and the sequenced “reads” can be 25–100 bps 
from one or both ends. The massive capacity of NGS al-
lows sequencing of multiple randomly overlapping DNA 
fragments. Therefore, all nucleotides in targeted regions 
may be included in many reads, allowing repeated anal-
ysis and depth of coverage. Increased depth of coverage 
usually improves sequencing accuracy and has a major 
influence on the performance of targeted capture for 
NGS.3
 Although NGS is becoming an important tool for 
genetic diagnosis, whole-genome sequencing (WGS) 
and WES remain expensive, and the volume of informa-
tion obtained hampers interpretation of the results. Re-
cently, target gene capture sequencing using gene panels 
has been applied to genetic diagnoses.2, 4 In particular, 
restricted target gene sequencing has high sequencing 
accuracy and deep achievable coverage of targeted 
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genes, giving rise to significant cost saving and feasible 
data sets for bioinformatic analyses that are functionally 
interpretable.3 The present study demonstrates that a 
targeted sequencing approach using gene panel testing is 
highly efficient for the diagnosis of Mendelian disorders.
SUBJECTS AND METHODS
Subjects
Patients were recruited for targeted gene testing from 
October 2014 through September 2015 at the Tottori 
University Hospital. Patients were divided into two 
groups of syndromic diagnoses and no syndromic di-
agnoses. The syndromic diagnosis group comprised 
patients who received specific diagnoses such as Sotos 
syndrome, Joubert syndrome, and Neuro-fibromatosis 
type 1. The no syndromic diagnosis group included pa-
tients with no specific diagnoses of epilepsy, polydacty-
ly, or intellectual disability (ID), among others (Tables 1 
and 2).
 Tests were performed after patients were informed 
of the risks and benefits and provided written informed 
consent. Informed written consent was obtained from 
adult subjects and parents of children. Each patient was 
informed about incidental findings, which were defined 
as conditions unrelated to the present symptoms. Ad-
ditionally, we explained that only genes related to the 
patient’s present symptoms would be investigated in this 
clinical study. Peripheral-blood samples were provided 
in all cases, and clinical data were collected from medi-
cal records. The study was approved by the ethics com-
mittee at the Tottori University (dated September 22, 
2014, approval number G152).
Table 1. Clinical Characteristics of 17 families, 
20 patients
Cohort (n = 20)
Gender
 Male 12
 Female 8
Age (years old)
 0–10 13
 10–20 3
 > 20 4
Group (n = 17)
 Syndromic diagnosis　(family: n = 17) 11
 No syndromic diagnosis 6
Previous exploration
 Array CGH 1
 Karyotype 12
CGH, comparative genomic hybridization.
Table 2. List of all patients in our study
Sex Age Phenotype Group Geneticdiagnosis Family history Genetic test
F1 M 1 year 11 months Joubert syndrome S AHI1 none G-band
F2 F 2 years Epilepsy, Macrocephaly, ID N FGFR3 none NSD1 gene, G-band
F3 F 4 years Sotos syndrome S NSD1 none FISH
F4 M 6 years Sotos syndrome S NSD1 none FISH
F5 F 31 years Nonsyndromic hearing loss S WFS1 none none
F6 F 47 years Neurofibromatosis type 1 S NF1 none none
F7 F 10 months Hydranencephaly S ND Sister (hydranencephaly) G-band
F8 M 2 years ID N ND none G-band
F9-1 F 3 years Polydactyly, Congenital heart disease, Craniosynostosis, ID N ND Brother (F9-2) G-band
F9-2 M 5 years Hydrocephaly, polydactyly N ND Sister (F9-1) G-band, Array CGH
F10 M 5 years Leigh syndrome S ND None mt-DNA
F11-1 M 6 years Joint hyperextension, ID N ND Brother (F11-2, 3) none
F11-2 M 9 years Joint hyperextension, ID N ND Brother (F11-1, 3) none
F11-3 M 12 years Joint hyperextension, ID N ND Brother (F11-1, 2) none
F12 M 7 years Anhidrotic ectodermal dysplasia S ND None Nemo gene
F13 M 7 years ID N ND None G-band
F14 M 10 years Congenital disorders of glycosylation S ND None G-band
F15 F 13 years Cyclic vomiting, peripheral neuropathy, ID N ND None G-band, mt-DNA
F16 M 42 years Arrhythmogenic right ventricular cardio-myopathy S ND Father and Sister none
F17 F 63 years Progressive Familial Intrahepatic Cholestasis S ND None none
AHI1, abelson helper integration site 1; CGH, comparative genomic hybridization; F, female; FGFR3, fibroblast growth factor receptor 
3; FISH, fluorescence in situ hybridization; ID, intellectual disability; M, male; N, non clinical diagnosis group; ND, not detective; NF1, 
neurofibromatosis type 1; NSD1, nuclear receptor binding SET domain protein 1; S, syndromic diagnosis group; WFS1, wolframin ER 
transmembrane glycoprotein.
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Library preparation and Sequencing
Genomic DNA was extracted from peripheral-blood 
samples. Targeted resequencing was performed using 
TruSight One sequencing panels (Illumina, San Diego, 
CA), which included 4,813 genes that are associated with 
known clinical phenotypes. TruSight one sequencing 
panels contain all the reagents required for amplifica-
tion, amplicon enrichment, and indexing of samples, and 
procedures were performed according the manufactur-
er’s instructions. After constructing the sequence library, 
a MiSeq next-generation sequencer (Illumina) was used 
to sequence 152-bp paired-end reads.
Bioinformatic pipeline and variant ranking
A bioinformatic pipeline was constructed in our insti-
tution to detect mutations (Fig. 1). Extracted data were 
mapped to a reference genome (GRCh37/hg19) using a 
Burrows-Wheeler Aligner (BWA). BWA is a software 
package for mapping low-divergent sequences against 
large reference genomes, such as the human genome. 
Variant calling and assembly of variant files were per-
formed using standard procedures with software such as 
SAMtools, genome analysis toolkit, and picard, which 
produce binary formats (BAM) from raw data. Vari-
ant filtering was performed using SnpEff and SnpSift 
software, which collects variant-specific information 
according to predicted pathogenicity (putative effects on 
protein, conservation scores, splice site predictions, and 
allelic frequencies in all patients, and in control cohorts 
such as the variant databases, Human Genetic Variation 
Database (HGVD), GWAS, and dbSNP. The HGVD is 
a Japanese mutation database. Additionally, to narrow 
candidate variants, we prepared a list of candidate genes 
for each symptom and clinical diagnosis (Table 3).
 Candidate variants were selected when harboring a 
frequency that was compatible with the incidence of the 
disease and expectedly accounted for less than 1%. Vari-
ants with suboptimal quality scores were removed from 
Syndromic	  diagnosis	  or	  phenotype
Candidate	  genes	  sequencing
4813	  gene	  targeted	  Sequencing	  
Iden:ﬁed	  variants
In	  muta:on	  data	  base?
Frequency	  <	  1%	  
Informa:on	  from	  another	  reports
Nonsynonymous?
Sanger	  sequencing
Diagnosis No	  diagnosis
Yes
No
Predicted	  to	  be	  pathogenic?
Candidate	  muta:on
Yes No
No
Yes
Yes Yes
Fig. 1. Flowchart for bioinformatic analyses.
Targeted resequencing was performed using a TruSight One sequencing panel (Illumina, San Diego, CA), which includes 4,813 genes. 
Data were mapped to a reference genome (GRCh37/hg 19), and variant calling using the bioinformatic pipeline was constructed in our fa-
cility. Variant filtering was performed using predicted pathogenicities and frequencies according to several mutation databases. Finally, we 
used the list of candidate genes to narrow candidate variants. In cases of the variant that were predicted to be pathogenic, we detected the 
variant as a candidate mutation, and all candidate mutations were validated using Sanger sequencing. 
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Table 3. Overview of gene list of our method
Brain malformation ARFGEF2  ARX  DCX  EOMES  FKRP  FKTN  FLNA  GPR56  LAMC3  LARGE  NDE1  OCLN  PAFAH1B1 
POMGNT1  POMT1  POMT2  PQBP1  RELN  SRPX2  TUBA1A  TUBA8  TUBB2B  TUBB3  VLDLR
Hereditary hearing 
loss
ACTG1  BSND  CCDC50  CDH23  CHRN  CLDN14  COCH  COL11A2  DFNA5  DFNB59  DIAPH1  DSPP  
ESPN  ESRRB  EYA4  FAM189A2  GJB2  GJB3  GJB6  GPSM2  GRHL2  GRXCR1  HGF  KCNQ4  LHFPL5  
LOXHD1  LRTOMT  MARVELD2  MIR96  MYH14  MYH9  MYO15A  MYO1A  MYO3A  MYO6  MYO7A  
OTOA  OTOF  P2RX2  PCDH15  POU3F4  POU4F3  PRPS1  PTPRQ  RDX  SIX1  SLC17A8  SLC26A4  
SLC26A5  SMPX  STRC  SYNE4  TECTA  TJP2  TMC1  TMIE  TMPRSS3  TPRN  TRIOBP  USH1C  WFS1  
Epilepsy ALDH7A1  ARFGEF2  ARHGEF9  ARX  ATP1A2  ATP2A2  ATP6AP2  ATP6V0A2  ATRX  CACNA1A  
CASK  CASR  CCDC88C  CDKL5  CHRNA2  CHRNA4  CHRNB2  CLCNKA  CLCNKB  CLN3  CLN5  
CLN6  CLN8  CNTNAP2  VPS13B  COL18A1  COL4A1  CPT2  CSTB  CTSD  CUL4B  OFD1  DCX  DEP-
DC5  DNAJC5  EFHC1  EMX2  EPM2A  FGD1  FGFR3  FKRP  FKTN  FLNA  FOXG1  GABRA1  GABRB3  
GABRD  GABRG2  GPC3  GPR56  GRIA3  GRIN2A  HSD17B10  KDM5C  KCNA1  KCNJ1  KCNJ10  KCN-
MA1  KCNQ2  KCNQ3  KCNT1  KCTD7  KIAA1279  LAMA2  LARGE  LBR  LGI1  MBD5  ME2  MECP2  
MEF2C  MFSD8  MLL2  NHLRC1  NIPBL  NOTCH3  NRXN1  OPHN1  PAFAH1B1  PAK3  PANK2  PAX6  
PCDH19  PEX7  PHF6  SERPINI1  PIGV  PLA2G6  PLP1  PNKP  POLG  POMGNT1  POMT1  POMT2  
PPT1  PQBP1  PRICKLE1  PRICKLE2  PRRT2  RAB39B  RAB3GAP1  RAI1  RELN  RNASEH2A  RNASE-
H2B  RNASEH2C  SAMHD1  SCARB2  SCN1A  SCN1B  SCN2A  SCN8A  SCN9A  SETBP1  SLC25A22  
SLC2A1  SLC4A10  SLC9A6  SMC1A  SMC3  SMS  SNAP29  SPTAN1  SRPX2  STXBP1  SYNGAP1  SYP  
TBC1D24  TBX1  TCF4  TPP1  TREX1  TSC1  TSC2  TUBA1A  TUBA8  TUBB2B  UBE3A  VPS13A  WDR62  
ZEB2 
Hereditary sensory 
and autonomic 
neuropathy
ATL1  CCT5  DNMT1  FAM134B  HSN2  IKBKAP  KIF1A  NGFB  NTRK1  RAB7  SCN9A  SPTLC1  
SPTLC2  WNK1  
Intellectual disability ABCC9  ABCD1  ABCD4  ABHD5  ACAD9  ACO2  ACOX1  ACSF3  ACSL4  ACTB  ACTG1  ACVR1  ADAR 
ADCK3  ADSL  AFF2  AGA  AGPAT2   AGTR2  AHCY  AHI1  AIFM1  AIMP1  AK1  AKT3  ALDH18A1  
ALDH3A2  ALG1  ALG12  ALG13  ALG2  ALG3  ALG6  ALG9  AMT  ANKH  ANKRD11  ANO10  AP1S2  
AP3B1  AP4B1  AP4E1  AP4S1  APTX  ARFGEF2  ARHGEF6  ARHGEF9  ARID1A  ARID1B  ARL13B  
ARL6  ARX  ASB11  ASL  ASPA  ASPM  ASXL1  ATP1A2  ATP2A2  ATP6AP2  ATP6V0A2  ATR  ATRX  
AUH  B3GALTL  B4GALT1  B4GALT7  BBS1  BBS10  BBS12  BBS2  BBS4  BBS5  BBS7  BBS9  BCKDHA  
BCKDHB  BCOR  BCS1L  BIVMERCC5  BLM  BRAF  BRWD3  BSCL2  BUB1B  C5orf42  CA2  CACNA1C  
CACNG2  CASK  CC2D1A  CC2D2A  CCBE1  CCDC78  CDH15  CDK5RAP2  CDKL5  CDON  CENPJ  
CEP135  CEP152  CEP290  CEP41  CHD7  CHKBCPT1B  CNTNAP2  COG1  COG7  COG8  COL4A1  
COL4A2  COLEC11  COQ2  COX15  CRBN  CREBBP  CTDP1  CTNNB1  CUL4  CYB5R3  D2HGDH  DBT  
DCX  DDHD2  DDX26B  DHCR24  DHCR7  DHFR  DHTKD1  DIP2B  DKC1  DLD  DLG3  DMD  DMPK  
DNAJC19  DNMT3B  DOCK8  DPAGT1  DPM1  DPYD  DYM  DYNC1H1  DYRK1A  EFTUD2  EHMT1  
EIF2AK3  ELOVL4  EMX2  ENOX2  EP300  EPB41L1  ERCC2  ERCC3  ERCC6  ERLIN2  ESCO2  ETHE1  
FANCB4  FANCD2  FAM120C  FBN1  FGD1  FGFR2  FGFR3  FH  FKRP   FKTN  FLNA  FMR1  FOXG1  
FOXP1  FRAS1  FTO  FTSJ1  FUCA1  GAD1  GALE  GALT  GAMT  GATAD2B  GATM  GCH1  GCSH  
GDI1  GFAP  GJC2   GK  GLDC  GLI3  GNAS  GNPAT  GNS  GPC3  GPHN  GPM6B  GPR56  GRIA3  
GRIK2  GRIN1  GRIN2A  GRIN2B  GSS  GTF2H5  GUCY2F  GUSB  HAX1  HCCS  HCFC1  HDAC4  
HDAC8  HESX1  HLCS  HOXA1  HPD  HPRT1  HRAS  HSD17B10  IDS  IDUA  IER3IP1  IGF1  IKBKG  
INPP5E  IQSEC2  ISPD  JAM3  KANSL1  KAT6B  KCNJ11  KCNK9  KCNQ2  KCNT1  KCTD7  KDM5C  
KDM6A  KIAA1279  KIF11  KIF7  KIRREL3  KLHL13  KMT2D  KRAS  KRBOX4  L1CAM  L2HGDH  
LAMA2  LAMC3  LAMP2  LARGE  LARP7  LIG4  LRP2  LRPPRC  MAGT1  MAN1B1  MANBA  MAOA  
MAP2K1  MAP2K2  MAT1A  MBD5  MCCC1  MCCC2  MCOLN1  MCPH1  MECP2  MED12  MED17  
MED23  MEF2C  MGAT2  MID1  MKKS  MLYCD  MMAA  MMACHC  MMADHC  MOCS1  MOCS2  
MPDU1  MPLKIP  MRPS22  MTR  MTRR  MUT  MVK  MYO5A  NAA10  NAGA  NAGLU  NBN  NDE1  
NDP  NDUFA1  NDUFA11  NDUFA12  NDUFS1  NDUFS2  NDUFS3  NDUFS4  NDUFS7  NDUFS8  
NDUFV1  NEU1  NF1  NHS  NIPBL  NKX2-1  NLGN3  NLGN4  NLGN4X  NLRP3  NPHP1  NRXN1  NSD1  
NSDHL  NSUN2  NTRK1  OCRL  OFD1  OPHN1  ORC1  PACS1  PAFAH1B1  PAK3  PANK2  PAX6  PC  
PCDH19  PCNT  PDHA1  PDSS1  PDSS2  PDZB11  PEPD  PEX1  PEX10  PEX11B  PEX13  PEX26  PEX5   
PEX7  PGK1  PHF6  PHF8  PHGDH  PIGN  PIGO  PIGV  PIK3R2  PLCB1  PMM2  PNKP  PNP  POC1A  
POLR3A  POLR3B  POMGNT1  POMT1  POMT2  PORCN  PPOX  PQBP1  PRODH  PRPS1  PRSS12  
PTCH1  PTCHD1  PTEN  PTPN11  PUS1  PVRL1  PYCR1  RAB18  RAB27A  RAB39B  RAB3GAP1  RAB-
3GAP2  RAB40AL  RAD21  RAF1  RAI1  RARS2  RELN  REPS2  RFT1  RMND1  RNASEH2A  RNASEH2B  
RNASEH2C  ROGDI  RPGRIP1L  RPS6KA3  SALL1  SATB2  SC5D  SCN1A  SCN2A  SCN8A  SCO2  SDHA  
SERAC1  SETBP1  SHH  SHOC2  SHROOM4  SIL1  SIX3  SKI  SLC12A6  SLC16A2  SLC17A5  SLC25A15  
SLC25A22  SLC2A1  SLC35C1  SLC4A4  SLC6A8  SLC9A6  SMAD4  SMARCA2  SMARCA4  SMARCB1  
SMC1A  SMC3  SMCX  SMOC1  SMPD1  SMS  SNAP29  SOBP  SOS1  SOX10  SOX2-OT  SOX3  SPRED1  
SRCAP  SRD5A3  SRPX2  ST3GAL3  STIL  STRA6  STXBP1  SUOX  SURF1  SYNGAP1  SYP  SYN1  SYT14  
TAT  TBC1D24  TBCE  TBX22  TCF4  TECR  TGFBR1  TGFBR2  THRB  TIMM8A  TMCO1  TMEM165  
TMEM231  TMEM237  TMEM67  TRAPPC9  TREX1  TRPC5  TSC1  TSC2  TSPAN7  TTC8  TUBA1A  
TUBB2B  TUSC3  UBE2A  UBE3A  UBR1  UPB1  UPF3B  VPS13B  WDR62  XPA  ZDHHC9  ZEB2  ZIC2  
ZNF41  ZNF592  ZNF674  ZNF711  ZNF81
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Leigh syndrome BCS1L  C12orf65  COX10  COX15  EARS2  ECHS1  FARS2  FOXRED1  GFM1  HIBCH  LRPPRC  MTFMT  
MT-ATP6  MT-ND1  MT-ND2  MT-ND3  MT-ND4  MT-ND5  MT-ND6  MT-TK  MT-TV  MT-TW  NDU-
FA1  NDUFA9  NDUFA10  NDUFA11  NDUFA2  NDUFA4  NDUFAF2  NDUFAF5  NDUFAF6  NDUFS1  
NDUFS2  NDUFS3  NDUFS4  NDUFS7  NDUFS8  NDUFV1  PET100  PDHA1  PDHB  PDSS2  POLG  
SCO2  SDHA  SDHAF1  SERAC1  SUCLA2  SUCLG1  SURF1  TACO1  TTC19  UQCRQ
Progressive familial 
intrahepatic cholesta-
sis
ATP8B1  ABCB11  ABCB4  TJP2
Macrocephaly ASPA  BRAF  CA2  CDKN1C  CLCN7  D2HGD  FGFR3  FMR1  GCDH  GFAP  GPC3  HEXA  HRAS  IDS  
IDUA  KRAS  L1CAM  LRP5  MEK1  MEK2  MLC1  NF1  NSD1  OSTM1  PLEKHM1  PTEN  PTPN11  
RAF1  SOS1  TCIRG1  TNFSF11  VG5Q
Skeletal dysplasia ACAN  ACVR1  ADAMTS10  ADAMTSL2  AGPS  ALPL  ALX4  ANKH  ARSE  BMPR1B  CA2  CASR  
CHST3  CLCN7  COL10A1  COL11A1  COL11A2  COL1A1  COL1A2CRTAP  COL2A1  COL9A1  COL9A2  
COL9A3  COMP  CRTAP  CTSK  CUL7  CXORF5  DDR2  DHCR24  DHPAT  DLL3  DLX3  DTDST  DYM  
DYNC2H1  EBP  EFNB  EIF2AK3  ESCO2  EVC1  EVC2  EXT1  EXT2  FBN1  FGF10  FGF23  FGF9  
FGFR1  FGFR2  FGFR3  FLNA  FLNB  GDF5  GDF5COMP  GJA1  GLI3  GNAS1  HOXA11  HOXD13  
HSPG2  IFT80  IHH  IKBKG  LBR  LEMD3  LEPRE  LFNG  LIFR  LMBR1  LMNA  LMX1B  LRP5  MATN3 
MESP2  MGP  MMP13  MMP2  MSX2  NEMO  NOG  NPR2  OSTM1  P63  PAPSS2  PCTN2  PEX7  PHEX  
PLOD2  POR  PPIB  PTHR1  RANKL  RECQL4  RMRP  ROR2  RUNX2  SALL1  SALL4  SBDS  SCYL1BP1  
SEDL  SHH  SHOX  SLC34A3  SMARCAL1  SOST  SOX9  TBCE  TBX15  TBX3  TBX4  TBX5  TBXAS1  
TCIRG1  TGFB1  TMEM16E  TNFRSF11A  TNFRSF11B  TNFSF11  TP63  TRIP11  TRPS1  TRPV4  TWIST1  
WISP3  WNT3  WNT7A  ZMPSTE24
Congenital Disorders 
of Glycosylation
ALDH18A1  ALDOB  ALG1  ALG11  ALG12  ALG13  ALG2  ALG3  ALG6  ALG8  ALG9  ATP6V0A2  
B3GALTL  B3GNT1  B4GALT1  BSCL2  CACNA1C  CANT1  CDH3  CEP290  CHRNE  CHST14  CHSY1  
CNTN4  COG1  COG4  COG5  COG6  COG7  COG8  COL1A1  COL1A2  CSF2RA  DAG1  DDOST  DOLK  
DPAGT1  DPM1  DPM2  DPM3  EIF2AK3  F13A1  FBN1  FBN2  FGA  FGF10  FGFR1  FGG  FKRP  FKTN 
G3GALNT2  G6PC3  GARS  GDNF  GFPT1  GH1  GMPPB  GPR143  GPR98  IFNGR1  IFNGR2  IL12B  
IL12RB1  ISPD  ITGB2  JAM3  LARGE  LHCGR  LMNA  LRP2  LRP5  MBTPS2  MGAT2  MOGS  MPDU1  
MPI  MYOC  NEU1  NGLY1  NRXN1  NTRK2  P2RX1  PDE4D  PGM1  PIGN  PKD1  PKHD1  PMM2  
PMP22  POMGNT1  POMGNT2  POMT1  POMT2  PRKAG2  PSAP  PYCR1  RELN  RET  RFT1  RHO  
RNASET2  RPGR  SEC23B  SERPINA7  SERPINC1  SGK196  SHH  SI  SIL1  SLC10A2  SLC26A4  SLC35A1  
SLC35A2  SLC35C1  SLC4A1  SLC4A11  SLC5A7  SPINK5  SPINT2  SRD5A1  SRD5A3  STAT1  STT3A  
STT3B  SYNE1  TGFBR1  TMEM15  TMEM165  TMEM5  TSHR  TYR  VPS45A  VWF  WFS1
Joubert syndrome AHI1  ARL13B  C5orf42  CC2D2A  CEP290 (NPHP6)  CEP41  INPP5E  KIF7  NPHP1  OFD1  RPGRIP1L  
TCTN1  TCTN2  TCTN3  TMEM138  TMEM216  TMEM231  TMEM237  TMEM67 (MKS3)
Hypohydrotic Ecto-
dermal dysplasia
EDA  EDAR  EDARADD
Arrhythmogenic 
Right Ventricular 
Dysplasia
DSC2  DSG2  DSP  JUP  PKP2  RYR2  TGFB3  TMEM43
consideration. Remaining variants were compared com-
putationally with the list of reported mutations from the 
Human Gene Mutation Database (HGMD). Variants in 
this database with minor allele frequencies of less than 
1% according to either HGVD were retained. Variants 
that are not described in the HGMD, including synony-
mous variants, intronic variants that were more than 5 
bp from exon boundaries (unlikely to affect messenger 
RNA splicing), and common variants (minor allele fre-
quency, > 1%) were also discarded.
Mutation validation
All candidate mutations were validated by Sanger se-
quencing, and co-segregation analyses were performed 
when possible.
RESULTS
Patient characteristics
Detailed clinical phenotypes of 17 families and 20 pa-
tients are provided in the clinical descriptions of patient 
section in Table 2. Subjects that were submitted to the 
clinical laboratory for targeted gene testing were primar-
ily pediatric patients. Clinical characteristics are pre-
sented in Table 1 and include 13 children younger than 
10 years (59%), 3 children and adolescents from 10 to 20 
years of age (18%), and 4 adults older than 20 years (24%; 
Table 1). Office settings of the ordering physicians were 
as follows: pediatrics (13 families), cardiology (1 fami-
ly), and gastroenterology (1 family). A total of 11 (65%) 
families had syndromic diagnoses and 6 (35%) families 
had no syndromic diagnoses. Samples were available 
from both parents for five families. The majority of pa-
tients had phenotypes that were related to intellectual 
123
Clinical diagnosis using NGS
Table 4. Overview of sequencing data of our method
Fam-
ily Raw reads
Un-
mapped 
reads
Read 
mapped 
(%)
Dupli-
cate 
reads 
(%)
Median 
cover-
age
Mean 
cover-
age
> 1x 
(%)
> 10x 
(%)
> 20x 
(%)
> 40x 
(%) Variant
EXON 
variant
Variant 
(freq < 
0.05)
EXON 
Variant 
(freq < 
0.05)
Variant 
(freq < 
0.01)
EXON 
variant 
(freq < 
0.01)
1 13324086 2602 99.98 3.23 40 43.69 98.73 89.62 76.53 48.74 26423 7080 4057 943 3297 691
2 9625914 1978 99.98 5.74 27 30.86 97.47 83.55 64.3 26.75 24607 7045 3751 927 3048 672
3 12116082 1956 99.98 14.05 36 43.65 97.5 86.14 72.03 44.71 23864 6910 4132 1020 3509 775
4 12164432 3055 99.97 3.17 37 41.06 98.9 89.67 75.27 44.97 27983 7300 3999 950 3339 729
5 9980608 2009 99.98 5.55 28 31.86 97.68 84.48 65.79 28.36 25371 6975 3750 902 3134 680
6 14588198 4130 99.97 3.46 42 46.15 98.41 90.33 78.48 52.48 28846 7241 4553 1053 3826 799
7 8989404 2419 99.97 4.92 27 33.16 97.23 80.34 61.54 31.57 21784 6970 3387 984 2834 756
8 9580736 2624 99.97 2.68 26 29.31 97.68 82.22 62.12 25.36 23113 6816 3305 876 2809 660
9-1 7061216 2349 99.97 3.75 20 25.23 95.8 73.27 49.97 18.9 20582 6622 2982 849 2493 646
9-2 8989404 2419 99.97 4.92 27 33.16 97.23 80.34 61.54 31.57 21784 6970 3387 984 2834 756
10 9625914 1978 99.98 5.74 27 30.86 97.47 83.55 64.3 26.75 24607 7045 3751 927 3048 672
11-1 9866094 5432 99.94 3.6 26 30.43 99.12 85.95 62.24 24.92 31105 7182 5410 1014 4731 801
11-2 6644172 5035 99.92 3.09 16 19.74 98.27 71.2 37.77 8.06 26623 6794 4552 977 3937 753
11-3 5527400 3323 99.94 3.24 15 18.76 96.47 64.86 35.17 8.64 20299 6721 3209 897 2689 656
12 13309866 2767 99.98 7.37 39 43.62 98.74 89.81 77.04 47.91 27920 7114 4538 1017 3762 769
13 10407584 2717 99.97 4.99 33 36.08 97.91 85.79 70.47 37.68 23220 7073 3516 948 2965 731
14 30800624 12121 99.96 10.43 80 100.32 99.68 97.1 91.82 77.41 37720 7433 6461 1120 5541 873
15 6600806 1192 99.98 11.67 20 25.74 94.28 71.3 49.32 20.23 15756 6542 2652 960 2250 752
16 16279852 7220 99.95 8.66 43 51.38 99.35 93.22 81.1 53.57 31755 7341 6033 1077 5193 839
17 17014786 4078 99.98 6.6 53 57.64 98.52 92.19 83.53 64.11 28550 7459 4749 1094 3962 839
disabilities (40%), and 13 of 20 patients had received 
chromosomal or other genetic tests, such as array com-
parative genomic hybridization (CGH) and fluorescence 
in situ hybridization (FISH) analysis.
Sequencing data and false-positive calls for SNVs
The median sequence coverage was 27.5, and an average 
of 84% of all targeted exons was covered by at least 10 
sequence reads (Table 4). Approximately, 15,000–37,000 
single-nucleotide variants and small insertion and dele-
tion changes were identified in each patient’s personal 
genome by comparison with the current reference hap-
loid human genome sequence (GRCh37/hg 19). After 
removing low-frequency variants and synonymous 
variants, an average of 742 exon variants per sample was 
analyzed for the 20 samples. No cases of detected caus-
ative genes showed false positives when confirmed by 
Sanger sequencing.
Diagnosis based on target resequencing
Positive diagnoses were observed in 5 of 11 (45%) pa-
tients of the syndromic diagnosis group and in 1 of 6 
(17%) of those in the no syndromic diagnosis group. We 
detected certainly causative mutations in 6 of 17 (35%) 
families, including five families with autosomal domi-
nant diseases and one with autosomal recessive disease. 
All five mutations of autosomal dominant diseases were 
described in HGMD (Table 5). Due to the absence of 
consent, parental studies were not performed in all five 
families, and one autosomal recessive family demon-
strated compound heterozygosity of two distinct muta-
tions. Nonetheless, parental studies indicated that pa-
tients inherited mutant alleles from each carrier parent, 
and both mutations were not present in HGMD. The c.841 
G > T mutation causes a stop codon. At the c. 2015 C > 
T mutation, the prediction of function using Polyphen2 
shows probably damaging. Additionally, this mutation 
was detected in two cases of Joubert syndrome at our 
facility, and both mutations were confirmed by Sanger 
sequencing.
DISCUSSION
Patient characteristics
Certainly causative mutations were detected in 6 of 17 
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Table 5. Summary of disease-causing mutations in 6 clinical cases
Age, y Gene Mutation References Inheritance Phenotype
F1 1 AHI1 E281X c.841 G > TT702M c.2105 C > T
In house data, prediction of 
function AR Joubert syndrome
F2 2 FGFR3 N540K c.1620 C > A 13 AD Hypochondroplasia
F3 4 NSD1 R2117Xc.6349 C > T 14 AD Sotos syndrome
F4 6 NSD1 T2055I c.6164 C > T 15 AD Sotos syndrome
F5 31 WFS1 D797Nc.2389 G > A 16 AD Nonsyndromic hearing loss
F6 47 NF1 W2208X c.6623 G > A 17 AD Neurofibromatosis-1
AD, autosomal dominant; AHI1, abelson helper integration site 1; AR, autosomal recessive; FGFR3, fibroblast growth factor receptor 3; 
NF1; neurofibromatosis type 1; NSD1, nuclear receptor binding SET domain protein 1; WFS1, wolframin ER transmembrane glycopro-
tein; y, year(s).
(35%) families. Among families who received genetic 
diagnoses, five in six were syndromically diagnosed 
before targeted gene testing. In the cases F2, F3 and F6 
(Tables 2 and 5), the size of NSD1 and NF1 genes was 
large, and no family history was found. To confirm the 
absence of other gene mutations, we used TruSight one 
gene panel sequencing instead of Sanger sequencing. In 
the case of F1 (Tables 2 and 5), Joubert syndrome has 
genetically heterogeneous. Accordingly, 19 genes were 
associated with Joubert syndrome in the OMIM data-
base. Recently, reports of causative genes have increased 
in number, and genetic heterogeneity of Mendelian 
disorders is more widely understood. Hence, genetic 
diagnosis using NGS is more important as a diagnostic 
alternate to Sanger sequencing.
 In the present study, most cases were children, and 
only four cases were adults. ID cases were identified in 
6 of 17 families. IDs are common neurodevelopmental 
disorders and are reported in 1.5%–2% of children and 
adolescents.5 Syndromic diagnoses of ID patients are 
made according to clinical symptoms but remain diffi-
cult even for experienced professional clinicians. How-
ever, although most ID disorders lack therapeutic drugs, 
understanding of genetic causes can benefit patients and 
families by providing prognostic information and pre-
cluding further unnecessary invasive testing. Moreover, 
diagnoses often facilitate access to appropriate medical 
and supportive care, and family members may benefit 
from knowledge of the risks of recurrence counseling 
and possible prenatal diagnoses.6 In the present study, 
physicians performed extensive clinical diagnostic work-
ups on some subjects before ordering gene panel testing, 
and some of these may have exceeded the time and cost 
of gene panel testing. For example, one patient (F2 in 
Table 2) had gene panel testing at 2 years of age follow-
ing evaluation using karyotype analysis, chromosomal 
CGH array analysis, and NSD1 single-gene sequencing 
tests. This patient carried a mutation in the FGFR3 gene, 
which is associated with hypochondroplasia. Bone dys-
plasia of this patient was mild and was unnoticed, and 
clinical diagnosis had been difficult. Thus, information 
from genetic diagnosis provides benefits for patient and 
families with genetic disorders and ID.
Target gene sequencing
Upon applying gene panel testing to genetic diagnoses 
of 17 families, we observed a molecular diagnostic yield 
of 35%, which was higher than the positive rates of oth-
er genetic tests, such as karyotype analysis (5%–15%) 
and chromosomal microarray analysis (30%).7 A recent 
study of diagnostic WES in 250 unselected, consecutive 
cases achieved a diagnostic yield of 25%,7 and another 
larger study of subjects with ID reached a diagnostic 
yield of 16%.6 Although comparisons of diagnostic 
yields between studies are statistically difficult, the re-
sults of the present study show higher rates of definitive 
genetic diagnosis than other genetic and chromosomal 
tests and WES reports, potentially reflecting testing of 
more specific subjects. Accordingly, among 2,000 WES 
samples, the molecular diagnosis rate was 36.1% in 
children with specific neurological findings (36.1%).7 In 
agreement, the present syndromic diagnostic rate was 
45%, whereas that among subjects of the no syndromic 
diagnosis group was only 17%.
 Genetic diagnosis of patients with certain clinical 
diagnoses and suspected causative genes are limited, 
warranting use of disease-restricted targeted gene panel 
sequencing, such as cancer panels, hearing loss panels, 
and muscular dystrophy panels. Hence, depending on 
specialization of facilities, disease-restricted targeted 
gene panel sequencing may be sufficient. Conversely, 
in facilities with patients carrying various diseases, 
multiple-restricted gene panels are required. However, 
numerous causative genes have been identified for het-
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erogeneous diseases such as ID. In these cases, a large 
number of gene-targeted panels, such as TruSight one 
gene panel, may find utility.
 Various clinical studies report diagnoses using Tru-
Sight one gene panels.9, 10 Accordingly, TruSight one 
gene panels target 4813 genes that are potentially associ-
ated with known clinical phenotypes. Because genes are 
numerous, suspected variants are also numerous, and in-
terpretations of variants remain poorly established. Ge-
netic diagnosis in approximately 35% of our six families 
with positive cases was based on disease-related gene 
mutations that were reported in mutation databases and 
in in-house data. However, most gene mutations that un-
derlie Mendelian disorders remain to be discovered. We 
expect that diagnostic rates of gene panel testing will in-
crease with the identification of additional patients who 
have mutations in novel candidate genes. Additionally, in 
undiagnosed cases, etiological mutations may be located 
in noncoding regions, such as regulatory or deep intron-
ic regions, and copy number variations are currently not 
detected by the present gene panel tests.
 NGS is used to sequence many randomly overlap-
ping DNA fragments. Moreover, increased depth of 
coverage usually improves sequencing accuracy. In this 
study, the depth of coverage at 20× was 66% and was 
lower than in another report using the Trusight one gene 
panel.11 Hence, low depth of coverage may influence 
sequencing accuracy. Although the necessity for confir-
mation of Sanger sequencing after NGS has not reached 
consensus, NGS variants with lower coverage of depth 
are likely sufficient for confirmation of Sanger sequenc-
ing-based diagnoses.12 In this study, we confirmed all 
mutations by Sanger sequencing and considered that this 
approach can compensate for the low depth of coverage.
 In conclusion, the use of the present gene panel test 
to analyze 17 clinical cases yielded diagnoses in 35% of 
cases. Hence, large numbers of gene-targeted panel tests 
are warranted as diagnostic tests for patients carrying 
nonspecific or unusual disease presentations with possi-
ble genetic causes and for patients with clinical diagno-
ses of heterogeneous genetic conditions.
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